Special channel feed – Endpoints News

Special channel feed

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Last month

Who’s leading LGBTQ+ inclusion in biopharma? Nominate them for Endpoints’ annual report

2 months ago

Will CRISPR matter?

2 months ago

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

4 months ago

Recapping the Endpoints 100: The biotech industry braces itself for Trump 2.0

4 months ago

Special report 2024: Meet 20 women breaking new ground in biopharma R&D

7 months ago

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

7 months ago

Endpoints 11 winner MediLink Therapeutics: China startup helps power the ADC renaissance

7 months ago

Endpoints 11 winner Lifordi Immunotherapeutics: Using antibodies to deliver potent steroids directly to immune cells

7 months ago

Endpoints 11 winner Iambic Therapeutics: Entering the ‘show-me’ era for AI

7 months ago

Endpoints 11 winner Cardurion Pharmaceuticals: A shot at one of heart disease’s 'undruggable' targets

7 months ago

Endpoints 11 winner Ascidian Therapeutics: A search-and-replace technology comes to RNA

7 months ago

Endpoints 11 winner Metsera: Clive Meanwell wagers on obesity after Medicines Company success

7 months ago

Endpoints 11 winner Xaira Therapeutics: Biotech’s largest AI bet with A-list backers

7 months ago

Endpoints 11 winner Formation Bio: A Silicon Valley-fueled unicorn aiming to be the next Roivant — or more

7 months ago

Endpoints 11 winner Capstan Therapeutics: Trying to win the in vivo CAR-T race

7 months ago

Endpoints 11 winner Mirador Therapeutics: Applying precision medicine to immune disease

7 months ago

Endpoints 11 winner Seaport Therapeutics: The Karuna team is back with another big bet in neuroscience

7 months ago

Checking up on past Endpoints 11 winners: Who went public, who got bought and who's still working

7 months ago

Biopharma leaders charting a path for the industry's LGBTQ+ community

10 months ago

Who are the women making a mark in biopharma R&D? Nominate them for Endpoints’ 2024 special report

11 months ago

The R&D 15: Top pharma players shell out record $153B for research, and M&A is a prime focus for all

Last year

The Endpoints 11: The biotech startups making the biggest bets with the most exciting science in 2023

Last year

These are biotech's 44 most promising startups of the last half-decade — here's how they've ended up

Last year

12 3 4 Next page Last page